Last reviewed · How we verify
2-chlorodeoxyadenosine
2-chlorodeoxyadenosine is a purine nucleoside analog that inhibits DNA synthesis.
2-chlorodeoxyadenosine is a purine nucleoside analog that inhibits DNA synthesis. Used for Acute myeloid leukemia, Chronic lymphocytic leukemia.
At a glance
| Generic name | 2-chlorodeoxyadenosine |
|---|---|
| Also known as | 2-CdA, Cladribin®, Leustatin® |
| Sponsor | North American Consortium for Histiocytosis |
| Drug class | purine nucleoside analog |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By incorporating into DNA, 2-chlorodeoxyadenosine causes DNA strand breaks and triggers apoptosis in rapidly dividing cells, such as lymphocytes. This mechanism is particularly effective against certain types of leukemia.
Approved indications
- Acute myeloid leukemia
- Chronic lymphocytic leukemia
Common side effects
- Myelosuppression
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Infection
Key clinical trials
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) (PHASE3)
- A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) (PHASE2)
- A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine (PHASE1)
- CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (PHASE1)
- A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
- Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
- Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 2-chlorodeoxyadenosine CI brief — competitive landscape report
- 2-chlorodeoxyadenosine updates RSS · CI watch RSS
- North American Consortium for Histiocytosis portfolio CI